Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
References
Behçet H. Über rezidivierende aphthöse, durch ein Virus Verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–7.
Shimizu T, Ehrlich GE, Inaba G et al. Behçet’s disease (Behçet’s syndrome). Semin Arthritis Rheum. 1979;8:223–60.
Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:148–55.
Direskeneli H. Autoimmunity vs autoinflammation in Behçet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45:1461–5.
Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum. 2004;50:2291–5.
Frassanito MA, Damacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999;42:1967–74.
Melikoglu M, Uysal S, Krueger JG et al. Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol. 2006;177:6415–21.
Azizlerli G, Köse AA, Saryca R et al. Prevalance of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42:803–6.
Saylan T, Mat C, Fresko I, Melikoglu M. Behçet’s disease in the Middle East. Clin Dermatol. 1999;17:209–23.
Marshall SE. Behçet’s disease. Best Prac Res Clin Rheumatol. 2004;18:291–311.
Chamberlain MA. Behçet’s syndrome in 32 patients in Yorkshire. Ann Rheum Dis. 1977;36:491–9.
O’Duffy JD. Summary of international symposium on Behçet’s disease. J Rheumatol. 1978;5:229–33.
Kural-Seyahi E, Fresko I, Seyahi N et al. The long-term mortality and morbidity of Behçet syndrome. A 2-decade outcome durvey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82:60–76.
Hamuryudan V, Yurdakul S, Moral F et al. Pulmonary arterial aneurysms in Behçet’s syndrome: a report of 24 cases. Br J Rheumatol. 1994;33:48–51.
Seyahi E, Ozdogan H, Yurdakul S et al. The outcome of children with Behçet’s syndrome. Clin Exp Rheumatol. 2004;22(Suppl. 34): 116a.
Yurdakul S, Tüzüner N, Yurdakul I, Hamuryudan V, Yazici H. Gastrointestinal involvement in Behçet’s syndrome: a controlled study. Ann Rheum Dis. 1996;55:208–10.
International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–80.
Soy M, Erken E, Konca K, Ozbek S. Smoking and Behçet’s disease. Clin Rheumatol. 2000;19:508–9.
Kaklamani VG, Markkomichelakis N, Kaklamanis PG. Could nicotine be benefical for Behçet’s disease. Clin Rheumatol. 2002;21:341–2.
Cottone M, Rossellini M, Orlanda A et al. Smoking habits and reccurence in Crohn’s disease. Gastroenterology. 1994;106:643–8.
Jick H, Walker AM. Cigarette smoking and ulcerative colitis. N Engl J Med. 1983;308:261–3.
Chajec T, Fainaru M. Behçet’s disease: report of 41 cases and review of the literature. Medicine. 1975;54:179–96.
Oshima Y, Shimizu T, Yokohari R et al. Clinical studies on Behçet’s syndrome. Ann Rheum Dis. 1963;22:36–45.
Yamamoto S, Toyokawa H, Matsubara J et al. A nation-wide survey of Behçet’s disease in Japan. 1. Epidemiological survey. Jpn J Ophthalmol. 1974;18:282–90.
Eun HC, Chung H, Choi SJ. Clinical analysis of 114 patients with Behçet’s disease. J Korean Med Assoc. 1984;27:933–9.
Dilsen N, Konice M, Aral O et al. Risk factors of vital organ involvement in Behçet’s disease. In: Weschler B, Godeau F, editors. Behçet’s Disease. Proceedings of the Sixth International Conference on Behçet’s Disease. Amsterdam: Excerpta Medica, 1993:165–9.
Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease. Semin Arthritis Rheum. 1998;27:197–217.
Bang D, Yoon KH, Chung HG, Choi EH, Lee ES, Lee S. Epidemiological and clinical features of Behçet’s disease in Korea. Yonsei Med J. 1997;38:428–36.
Bang D, Lee JH, Lee ES et al. Epidemiologic and clinical survey of Behçet’s disease in Korea: the first multicenter study. J Korean Med Sci. 2001;16:615–18.
Chang HK, Kim JW. The clinical features of Behçet’s disease in Yongdong districts: analysis of a cohort followed from 1997 to 2001. J Korean Med Sci. 2002;17:784–9.
Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol. 2003;42:346–51.
O’Duffy JD, Carney A, Deodhar S. Behçet’s disease: report of 10 cases, 3 with new manifestation. Ann Intern Med. 1971;75:561–70.
Jankowski J, Crombie I, Jankowski R. Behçet’s syndrome in Scotland. Postgrad Med J. 1992;68:566–70.
Cakir N, Pamuk ON, Dervis E et al. The prevalance of rheumatologic diseases in Havsa: the initial evaluation. Annual European Congress of Rheumatology, Vienna, Austria. Ann Rheum Dis. 2005;64(Suppl. III): 551.
Puspok A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum. 2000;43:685–91.
Laine L, Connors LG, Reicin A et al. Serious lower gastrointestinal clinical events with nonselective NSAID or Coxib use. Gastroenterology. 2003;124:288–92.
Korman U, Cantasdemir M, Kurugoglu S et al. Enteroclysis findings of intestinal Behçet disease: a comparative study with Crohn disease. Abdom Imaging. 2003;28:308–12.
Kim JS, Lim SH, Choi IJ et al. Prediction of the clinical course of Behçet’s colitis according to macroscopic classification by colonoscopy. Endoscopy. 2000;32:635–40.
Ramzan NN, Leighton JA, Heigh RI, Shapiro MS. Clinical significance of granuloma in Crohn’s disease. Inflamm Bowel Dis. 2002;8:168–73.
Pulimood AB, Ramakrishna BS, Kurian G et al. Endoscopic mucosal biopsies are useful in distinguishing granulomatous colitis due to Crohn’s disease from tuberculosis. Gut. 1999;45:537–41.
Fukuda Y, Watanabe I. Pathological studies on intestinal Behçet’s (entero-Behçet’s) disease. In: Dilşen N, Koniçe M, Övül C, editors. Behçet’s Disease. Proceedings of an international symposium on Behçet’s disease. London: Royal Society of Medicine Services, 1986:289.
Celik AF, Hatemi I. Gastrointestinal involvement of Behçet’s syndrome. Turkiye Klinikleri J Int Med Sci. 2005;1:48–54.
Su CG, Judge TA, Leichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin N Am. 2002;31:307–21.
Yurdakul S, Yazici H, Tuzun Y et al. The arthritis of Behçet’s disease: a prospective study. Ann Rheum Dis. 1983;42:505–15.
Chou SJ, Chen TK, Jan HC, Lou MA, Liu YM. Intestinal perforations in Behçet’s disease. J Gastrointest Surg. 2007;11:508–14.
Hatemi I, Hatemi G, Celik A et al. İnflamatuvar barsak hastalığında Behçet sendromu sıklı ği. Romatoloji Kongre Kitabı. 2006, İzmir, 115:127.
Uyar FA, Saruhan-Direskeneli G, Gül A. Common Crohn’s disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behçet’s disease in Turkey. Clin Exp Rheumatol. 2004;22(Suppl. 34):S50–2.
Ahmad T, Zhang L, Gogus F et al. CARD 15 polymorphisms in Behçet’s disease. Scand J Rheumatol. 2005;34:233–7.
Ozen SC, Dagli U, Kilic MY et al. NOD2/CARD15, NOD1/CARD4, and ICAM-1 gene polymorphisms in Turkish patients with inflammatory bowel disease. J Gastroenterol. 2006;41:304–10.
Krause I, Monselise Y, Milo G, Weinberger A. Anti-Saccharomyces cerevisiae antibodies — a novel serologic marker for Behçet’s disease. Clin Exp Rheumatol. 2002;20(Suppl. 26):S21–4.
Fresko I, Ugurlu S, Ozbakir F et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet’s syndrome. Clin Exp Rheumatol. 2005;23(Suppl. 38):S67–70.
Choi CH, Kim TI, Kim BC et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behç et’s disease patients: relation to clinical course. Dis Colon Rectum. 2006;49:1849–59.
Govid KM, Sachdev V, Gupta R, Lal S, Pandey RM. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosis. Dig Dis Sci. 2007;52:33–9.
Naganuma M, Iwao Y, Inoue N et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet’s disease. Am J Gastroenterol. 2000;95:2848–51.
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease. Gastroenterology. 2001;120:995–9.
Travis SP, Czajkowski M, McGovern DP et al. Treatment of intestinal Behçet’s syndrome with chimeric tumor necrosis factor alpha antibody. Gut. 2001;49:725–8.
Lee JH, Kim TN, Choi ST et al. Remission of intestinal Behçet’s disease treated with anti-tumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med. 2007;22:24–7.
Celik AF, Seyahi EK, Coskun S et al. Thalidomide in azathioprine resistant gastrointestinal (GI) Behçet’s syndrome: 3 cases. Clin Exp Rheumatol. 2004;22(Suppl. 34).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer and Falk Foundation e.V.
About this chapter
Cite this chapter
çelik, A.F., Pamuk, Ö.N., Melikoğlu, M., Yazici, H. (2008). How to diagnose Behçet’s and intestinal Behçet’s disease?. In: Tözün, N., Dağlı, Ü., Mantzaris, G., Schölmerich, J. (eds) IBD 2007 — Achievements in Research and Clinical Practice. Falk Symposium, vol 159. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6987-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6987-1_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6986-4
Online ISBN: 978-1-4020-6987-1
eBook Packages: Medicine (R0)